Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 1;4(11):e2137575.
doi: 10.1001/jamanetworkopen.2021.37575.

Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma

Lindsey Wang  1   2 , Nathan A Berger  2   3 , Rong Xu  1   3
Affiliations

Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma

Lindsey Wang et al. JAMA Netw Open. .

Abstract

This cohort study assesses the risk of breakthrough SARS-CoV-2 infection and hospitalization among fully vaccinated patients with multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Berger reported grants from the National Institutes of Health (NIH) during the conduct of the study. No other disclosures were reported.

Figures

Figure.
Figure.. Risk of Hospitalization for Patients With vs Without Breakthrough COVID-19 Infection
Kaplan-Meier curves for hospitalization in the breakthrough cohort (fully vaccinated patients with breakthrough infections) with hospitalizations followed starting from the day of breakthrough infections up to October 8, 2021, and in the no-breakthrough cohort (fully vaccinated patients without breakthrough infections) with hospitalizations followed starting at 14 days after full vaccinations up to October 8, 2021. The 2 cohorts were propensity score matched for demographics, adverse socioeconomic determinants of health, transplants, comorbidities, characteristics of multiple myeloma (status, stage, lymphocyte counts), COVID-19-related medications, multiple myeloma treatments (chemotherapy, target therapy, radiation therapy, and stem cell transplant), and vaccine types. Shaded areas represent 95% CIs.
See this image and copyright information in PMC

References

    1. Wang Q, Berger NA, Xu R. When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities. Blood Rev. 2021;47:100775. doi:10.1016/j.blre.2020.100775 - DOI - PMC - PubMed
    1. Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2021;7(2):220-227. doi:10.1001/jamaoncol.2020.6178 - DOI - PMC - PubMed
    1. Van Oekelen O, Gleason CR, Agte S, et al. ; PVI/Seronet team . Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39(8):1028-1030. doi:10.1016/j.ccell.2021.06.014 - DOI - PMC - PubMed
    1. Re D, Barrière J, Chamorey E, et al. . Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies. Leuk Lymphoma. 2021;1-3. doi:10.1080/10428194.2021.1957877 - DOI - PubMed
    1. TriNetX Analytics Network . Accessed October 8, 2021. https://trinetx.com/

Publication types

MeSH terms

Substances

Supplementary concepts